CRP on Radiobiological and Clinical Studies on Viral-Induced Cancer's Response to Radiotherapy
CRP on Radiobiological and Clinical Studies on Viral-induced Cancer's Response to Radiotherapy With Comprehensive Morbidity Assessment
Sponsor: International Atomic Energy Agency
This PHASE3 trial investigates Cervix Cancer and is currently completed. International Atomic Energy Agency leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Nov 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- International Atomic Energy Agency
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bahawalpur, Pakistan, Cape Town, South Africa, Lima, Peru, Manchester, United Kingdom, Mississauga, Canada, Mumbai, India, Porto Alegre, Brazil, Rabat, Morocco, Seoul, South Korea, Skopje, North Macedonia and 1 more location